GT Biopharma, Inc. Cash Flow Statement
GTBP|8 years of annual SEC 10-K data (FY2011-FY2020)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
GT Biopharma, Inc. used $4M in operating cash flow in FY2020.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$38.6M | $9.8M | -$32.7M | -$23.5M | -$501.0K | -$5.2M | -$3.7M | -$3.0M |
| Depreciation & Amortization | $4.0K | $1.0K | $2.0K | $0 | - | - | - | - |
| Operating Cash Flow | -$3.7M | -$1.9M | -$4.7M | -$1.7M | -$442.0K | -$987.0K | -$963.0K | -$1.5M |
| Capital Expenditures | - | $0 | $1.0K | $6.0K | $0 | $2.0K | $0 | - |
| Free Cash Flow | - | -$1.9M | -$4.7M | -$1.8M | -$442.0K | -$989.0K | -$963.0K | - |
| FCF Margin | - | - | -17251.8% | -2877.0% | -120.1% | -289.2% | -3703.8% | - |